抗体阻害剤

製品コード 製品名 製品説明
A2006 Bevacizumab
A2007 Trastuzumab
A2008 Pertuzumab
A2009 Rituximab
A2010 Adalimumab
A2011 Sarilumab
A2012 Tocilizumab
A2002 Nivolumab Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities.
A2004 Atezolizumab Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1.
A2005 Pembrolizumab Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities.
A2000 Cetuximab Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation.
A2001 Ipilimumab Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.